Within the past decade, T-cell-targeted immunomodulators directed against the immune checkpoints of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand (PD-L1) have revolutionized cancer treatment for several types of tumors [125]. The gene discussed is PDCD1; the disease is cancer.